+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 0 - 39Years
All Genders
ID06892678

DFMO Oral Treatment to Prevent Relapse in Patients Under 40 With Relapsed Ewing Sarcoma or Osteosarcoma After Therapy

Led by Montefiore Medical Center · Updated on 2026-05-14

15

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to determine if it is feasible to give DL-alpha-difluoromethylornithine DFMO to patients with relapsed Ewing sarcoma or osteosarcoma who have finished all planned treatments and show no signs of disease. These cancers often relapse, leading to poor outcomes, and DFMO, a synthetic analog of ornithine, has been studied in various cancers and approved by the FDA to reduce relapse risk in certain high-risk cancers. The study explores whether DFMO can help prevent recurrence in these patients. Participants will receive DFMO orally twice daily in 28-day cycles. The dose depends on the patients body surface area, with tablets provided in specific amounts ranging from one to four tablets per dose. The tablets may be swallowed whole, chewed, or mixed with food or liquid. This treatment will continue for up to two years to assess feasibility and outcomes. During the study, patients will be monitored for how well they tolerate DFMO and for any signs of cancer recurrence. Researchers will assess feasibility of administering DFMO and track event-free survival for up to two years. Patients need to meet specific health and recovery criteria before starting and will have regular assessments to monitor blood counts, kidney and liver function, and overall health throughout the study period.

CONDITIONS

Brief Title

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Research Team

R

Rebecca Zylber, MSN

L

Lara Fabish, MSN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here